Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.

Rafael Guimarães Dos SantosFrancisco S GuimarãesJosé Alexandre S CrippaJaime E C HallakGiordano Novak RossiJuliana Mendes RochaAntônio W Zuardi

Published in: Expert opinion on drug metabolism & toxicology (2020)

SAEs related to CBD in RCT are rare and include mainly elevated transaminases, convulsion, sedation, lethargy, and upper respiratory tract infections. Elevated transaminases are related to concomitant valproate use, while sedation, lethargy, and upper respiratory tract infections are related to concomitant clobazam use. Epileptic patients should be monitored when using CBD concomitantly with these and other antiepileptic drugs for other possible drug-drug interactions.

Keyphrases

respiratory tract
end stage renal disease
chronic kidney disease
ejection fraction
mechanical ventilation
intensive care unit
acute respiratory distress syndrome
adverse drug
patient reported